https://doi.org/10.4081/reumatismo.2008.61

Neprhrotic syndrome in a patient with rheumatoid arthritis treated with adalimumab: a case report

Vol. 60 No. 1 (2008)
Abstract Views: 1140
PDF: 855
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Authors

M.G. Portuesi
office@pagepress.org
P. Perosa
The pathogenetic role of TNFα in inflammatory diseases has been known for a long time and has modified the therapeutic approach towards this pathology. All over the word, about 400.000 patients have been treated with biological anti-TNFα drugs. Particular attention has been taken for the safety of their use. Let us describe a case of 60 year old man affected by rheumatoid arthritis who has developed nephrotic syndrome with histological pattern typical of systemic lupus erythematosus-like syndrome, without autoantibodies.

Altmetrics

Downloads

Download data is not yet available.

Citations

Crossref
Scopus
Google Scholar
Europe PMC

How to Cite



Neprhrotic syndrome in a patient with rheumatoid arthritis treated with adalimumab: a case report. (2008). Reumatismo, 60(1), 61-63. https://doi.org/10.4081/reumatismo.2008.61

PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.